Activation of LncRNA TINCR by H3K27 Acetylation Promotes Trastuzumab Resistance and Epithelial-mesenchymal Transition by Targeting MicroRNA-125b in Breast Cancer

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2019 Jan 10

PMID 30621694

Citations 130

Authors

Huaying Dong

Jianguo Hu

Kejian Zou

Mulin Ye

Yuanwen Chen

Chengyi Wu

Xin Chen

Mingli Han

Affiliations

Soon will be listed here.

Abstract

Background: Trastuzumab resistance followed by metastasis is a major obstacle for improving the clinical outcome of patients with advanced human epidermal growth factor receptor 2-positive (HER-2+) breast cancer. While long non-coding RNAs (lncRNAs) can modulate cell behavior, the contribution of these RNAs in trastuzumab resistance and metastasis of HER-2+ breast cancer is not well known. In this study, we sought to identify the regulatory role of lncRNA in trastuzumab resistance and accompanied Epithelial-mesenchymal Transition (EMT) process in advanced HER-2+ breast cancer.

Methods: Trastuzumab-resistant SKBR-3-TR and BT474-TR cell lines were established by grafting SKBR-3 and BT474 cells into mouse models and subjected to trastuzumab treatment. LncRNA microarray followed by quantitative reverse transcription PCR (qRT-PCR) was carried out to verify the differentially expressed lncRNAs. Western blotting, bioinformatics analysis, immunofluorescence assay and immunoprecipitation assays (ChIP and RIP) were performed to identify the involvement and functional interactions between H3K27 acetylation and terminal differentiation-induced non-coding RNA (TINCR) or between TINCR and its downstream genes including miR-125b, HER-2 and Snail-1. In addition, a series of in vitro and in vivo assays were performed to assess the functions of TINCR.

Results: An increase in both, IC value of trastuzumab and EMT was observed in the established trastuzumab-resistant cell lines. The expression level of TINCR was significantly increased in trastuzumab-resistant cells when compared with sensitive cells. Knockdown of TINCR reversed the trastuzumab resistance and the acquired EMT in these cells. TINCR was detected in the cytoplasm of breast cancer cells and could sponge miR-125b, thereby releasing HER-2 and inducing trastuzumab resistance. In addition, Snail-1 was found to be the target gene of miR-125b and overexpression of Snail-1 could reverse the suppressed migration, invasion, and EMT caused by TINCR silencing. The upregulation of TINCR in breast cancer was attributed to the CREB-binding protein (CBP)-mediated H3K27 acetylation at the promoter region of TINCR. Clinically, HER-2+ breast cancer patients with high TINCR expression levels were associated with poor response to trastuzumab therapy and shorter survival time.

Conclusion: TINCR could promote trastuzumab resistance and the accompanied EMT process in breast cancer. Therefore, TINCR might be a potential indicator for prognosis and a therapeutic target to enhance the clinical efficacy of trastuzumab treatment.

Citing Articles

Despicable role of epithelial-mesenchymal transition in breast cancer metastasis: Exhibiting restorative regimens.

Famta P, Shah S, Dey B, Kumar K, Bagasariya D, Vambhurkar G Cancer Pathog Ther. 2025; 3(1):30-47.

PMID: 39872366 PMC: 11764040. DOI: 10.1016/j.cpt.2024.01.001.

LncRNA FEZF1-AS1 promotes pulmonary fibrosis via up-regulating EZH2 and targeting miR-200c-3p to regulate the ZEB1 pathway.

Liu M, Song L, Lai Y, Gao F, Man J Sci Rep. 2024; 14(1):26044.

PMID: 39472569 PMC: 11522518. DOI: 10.1038/s41598-024-74570-7.

E-Cadherin Induces Serine Synthesis to Support Progression and Metastasis of Breast Cancer.

Lee G, Wong C, Cho A, West J, Crawford A, Russo G Cancer Res. 2024; 84(17):2820-2835.

PMID: 38959339 PMC: 11374473. DOI: 10.1158/0008-5472.CAN-23-3082.

Activation of lncRNA DANCR by H3K27 acetylation regulates proliferation of colorectal cancer cells.

Han Y, Shan T, Huang H, Song M, Chen L, Li Q Discov Oncol. 2024; 15(1):249.

PMID: 38940959 PMC: 11213841. DOI: 10.1007/s12672-024-01124-8.

Expression and Significance of LINC02418 in Breast Cancer.

Zhou Y, Huang J Breast Cancer (Dove Med Press). 2024; 16:233-243.

PMID: 38694704 PMC: 11061563. DOI: 10.2147/BCTT.S454054.

References

Veneziani B, Criniti V, Cavaliere C, Corvigno S, Nardone A, Picarelli S . In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches. Mol Cancer Ther. 2007; 6(12 Pt 1):3091-100. DOI: 10.1158/1535-7163.MCT-07-0356. View

Hayashi N, Niikura N, Yamauchi H, Nakamura S, Ueno N . Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer. Breast Cancer Res Treat. 2012; 137(2):523-31. PMC: 3860360. DOI: 10.1007/s10549-012-2336-6. View

Hicks D, Kulkarni S . Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. Arch Pathol Lab Med. 2008; 132(6):1008-15. DOI: 10.5858/2008-132-1008-TAATFE. View

Wolff A, Hammond M, Schwartz J, Hagerty K, Allred D, Cote R . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2006; 25(1):118-45. DOI: 10.1200/JCO.2006.09.2775. View

Narayan M, Wilken J, Harris L, Baron A, Kimbler K, Maihle N . Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res. 2009; 69(6):2191-4. DOI: 10.1158/0008-5472.CAN-08-1056. View

Loewen G, Jayawickramarajah J, Zhuo Y, Shan B . Functions of lncRNA HOTAIR in lung cancer. J Hematol Oncol. 2014; 7:90. PMC: 4266198. DOI: 10.1186/s13045-014-0090-4. View

Fatica A, Bozzoni I . Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2013; 15(1):7-21. DOI: 10.1038/nrg3606. View

Nakagawa S, Kageyama Y . Nuclear lncRNAs as epigenetic regulators-beyond skepticism. Biochim Biophys Acta. 2013; 1839(3):215-22. DOI: 10.1016/j.bbagrm.2013.10.009. View

Kornienko A, Guenzl P, Barlow D, Pauler F . Gene regulation by the act of long non-coding RNA transcription. BMC Biol. 2013; 11:59. PMC: 3668284. DOI: 10.1186/1741-7007-11-59. View

10.

Ni W, Zhang Y, Zhan Z, Ye F, Liang Y, Huang J . A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1. J Hematol Oncol. 2017; 10(1):91. PMC: 5395742. DOI: 10.1186/s13045-017-0449-4. View

11.

Han P, Li J, Zhang B, Lv J, Li Y, Gu X . The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling. Mol Cancer. 2017; 16(1):9. PMC: 5237133. DOI: 10.1186/s12943-017-0583-1. View

12.

Li W, Zhai L, Wang H, Liu C, Zhang J, Chen W . Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer. Oncotarget. 2016; 7(19):27778-86. PMC: 5053687. DOI: 10.18632/oncotarget.8413. View

13.

Shi S, Wang L, Yu B, Li Y, Jin Y, Bai X . LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget. 2015; 6(13):11652-63. PMC: 4484483. DOI: 10.18632/oncotarget.3457. View

14.

Zhu H, Bai W, Ye X, Yang A, Jia L . Long non-coding RNA UCA1 desensitizes breast cancer cells to trastuzumab by impeding miR-18a repression of Yes-associated protein 1. Biochem Biophys Res Commun. 2018; 496(4):1308-1313. DOI: 10.1016/j.bbrc.2018.02.006. View

15.

Kretz M . TINCR, staufen1, and cellular differentiation. RNA Biol. 2013; 10(10):1597-601. PMC: 3866239. DOI: 10.4161/rna.26249. View

16.

Xu T, Wang Y, Xiong W, Ma P, Wang W, Chen W . E2F1 induces TINCR transcriptional activity and accelerates gastric cancer progression via activation of TINCR/STAU1/CDKN2B signaling axis. Cell Death Dis. 2017; 8(6):e2837. PMC: 5520882. DOI: 10.1038/cddis.2017.205. View

17.

Zhu Z, He J . TINCR facilitates non-small cell lung cancer progression through BRAF-activated MAPK pathway. Biochem Biophys Res Commun. 2018; 497(4):971-977. DOI: 10.1016/j.bbrc.2018.02.059. View

18.

Zheng Y, Yang C, Tong S, Ding Y, Deng W, Song D . Genetic variation of long non-coding RNA TINCR contribute to the susceptibility and progression of colorectal cancer. Oncotarget. 2017; 8(20):33536-33543. PMC: 5464888. DOI: 10.18632/oncotarget.16538. View

19.

Chen Z, Liu Y, He A, Li J, Chen M, Zhan Y . Theophylline controllable RNAi-based genetic switches regulate expression of lncRNA TINCR and malignant phenotypes in bladder cancer cells. Sci Rep. 2016; 6:30798. PMC: 5009373. DOI: 10.1038/srep30798. View

20.

Liu Y, Du Y, Hu X, Zhao L, Xia W . Up-regulation of ceRNA TINCR by SP1 contributes to tumorigenesis in breast cancer. BMC Cancer. 2018; 18(1):367. PMC: 5883880. DOI: 10.1186/s12885-018-4255-3. View